INAB (IN8bio) Short Percentage of Float


INAB IN8bio Inc INAB
24 GF Score
Price $1.36
View Full Analysis

What is IN8bio Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

INAB vs ZIVO, LPCN, CTXR: Short Percentage of Float Comparison

For the Biotechnology subindustry, IN8bio's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IN8bio Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where IN8bio's Short Percentage of Float falls into.


INAB
24GF Score
IN8bio Inc INAB
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IN8bio Business Description

Address 350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
24GF Score

Get the complete analysis for INAB

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.36
Price